Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule DOI and DOC

In this episode, Joe interviews renowned chemist, filmmaker, and journalist, Hamilton Morris.  After originally backing down from its first attempt in 2022, the DEA is once again looking to apply schedule I status to two lesser-known compounds: DOI (2,5-dimethoxy-4-iodoamphetamine) and DOC (2,5-dimethoxy-4-chloroamphetamine). For decades, DOI and DOC have been incredible tools for researchers studying serotonin […] The post Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule DOI and DOC appeared first on Psychedelics Today.